Seroconversion of Hbsag in Melanoma Patient with Hepatitis B Treated with Checkpoint Inhibitors: A Case Report
Biotherapy Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, P.R China
- *Corresponding Author:
- Xiaoshi Zhang
Biotherapy Center, State Key Laboratory of Oncology in South China
Sun Yat-sen University Cancer Center, P.R China
Tel: +86 20 86-20-87343383
E-mail: [email protected]
Received Date: April 17, 2017; Accepted Date: April 20, 2017; Published Date: April 25, 2017
Citation: Wen X, Ding Y, Zhu B, Li D, Li J, et al. (2017) Seroconversion of Hbsag in Melanoma Patient with Hepatitis B Treated with Checkpoint Inhibitors: A Case Report. J Clin Case Rep 7:951. doi: 10.4172/2165-7920.1000951
Copyright: © 2017 Wen X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Based on remarkable and sustained antitumor activity, the anti-CTLA-4 antibody ipilimumab, and anti-PD1 antibodies nivolumab and pembrolizumab have been approved for treatment of advanced melanoma. As checkpoint blockade is associated with potentially serious immune-related adverse events, including autoimmune hepatitis, clinical trials evaluating these agents have excluded patients with chronic hepatitis B virus infection. Herein, we describe one patient with advanced melanoma and concomitant HBV infections experiencing seroconversion of HBsAg after treatment with combination of PD-1 and CTLA-4 blockade.